Shares of ProPhase Labs, Inc. (PRPH) have been struggling lately and have lost 21% over the past week. However, a hammer ...

ProPhase Labs (NASDAQ:PRPH – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

I n a challenging market environment, ProPhase Labs Inc. (PRPH) stock has touched a 52-week low, dipping to $0.56, marking a stark contrast to its 52-week high of $7.48. This price level reflects ...

This quarter's event is focused on MicroCap companies who are undervalued and have a catalyst. ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer ...

ProPhase Labs, Inc. GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer ...

ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations ...

ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered ...

ProPhase Labs (PRPH) is focused on immediate cash generation through two key initiatives: strategic alternatives including a potential sale of its genomics assets and the aggressive collection of ...

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare ...

The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows that PLK1 inhibition delays activation of CDK1-cyclin B and halts cells for ...